BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $109 | -16.8% | 2,883 | 0.0% | 0.01% | -13.3% |
| Q2 2023 | $131 | +12.0% | 2,883 | 0.0% | 0.02% | 0.0% |
| Q1 2023 | $117 | -100.0% | 2,883 | -6.5% | 0.02% | -48.3% |
| Q1 2022 | $239,000 | -9.8% | 3,084 | 0.0% | 0.03% | -3.3% |
| Q4 2021 | $265,000 | +6.9% | 3,084 | 0.0% | 0.03% | -3.2% |
| Q3 2021 | $248,000 | +17.0% | 3,084 | -8.9% | 0.03% | -16.2% |
| Q3 2017 | $212,000 | +3.4% | 3,384 | 0.0% | 0.04% | 0.0% |
| Q2 2017 | $205,000 | -16.3% | 3,384 | -3.6% | 0.04% | -42.2% |
| Q2 2015 | $245,000 | -10.9% | 3,510 | -12.5% | 0.06% | -4.5% |
| Q1 2015 | $275,000 | -6.5% | 4,010 | 0.0% | 0.07% | -4.3% |
| Q4 2014 | $294,000 | +2.1% | 4,010 | 0.0% | 0.07% | 0.0% |
| Q3 2014 | $288,000 | -0.7% | 4,010 | 0.0% | 0.07% | +1.4% |
| Q2 2014 | $290,000 | -3.0% | 4,010 | -1.2% | 0.07% | -8.0% |
| Q1 2014 | $299,000 | +4.5% | 4,060 | -1.2% | 0.08% | -1.3% |
| Q4 2013 | $286,000 | +4.8% | 4,110 | -1.2% | 0.08% | -3.8% |
| Q3 2013 | $273,000 | -6.5% | 4,160 | -1.2% | 0.08% | -9.2% |
| Q2 2013 | $292,000 | – | 4,210 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |